Clinical Trial Update: BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab [Phase 3]

View source ↗

Summary

Phase 3 trial comparing chemotherapy plus trastuzumab versus chemotherapy plus trastuzumab plus bevacizumab in HER2-positive breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: NSABP Foundation Inc | Conditions: Breast Cancer | Phase 3 | Status: TERMINATED